News

GRI Bio Strengthens Global Patent Holdings for NKT Therapies

GRI Bio Strengthens Global Patent Holdings for NKT Therapies

GRI Bio Expands Intellectual Property with Global Patent Grants

GRI Bio, Inc. is taking significant strides towards strengthening its intellectual property (IP) portfolio with the recent granting of two global patents. This progression highlights the company’s unwavering commitment to developing its innovative pipeline of Natural Killer T (NKT) cell modulators targeted at addressing inflammatory, fibrotic, and autoimmune diseases.

Details of the Granted Patents

The two notable patents recently granted encompass:

European Patent on NKT Cell Modulators

The European patent application No. 19,166,502 is titled “Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use.” This patent secures rights for GRI-0803, an innovative activator of human type 2 diverse NKT (dNKT) cells, aimed at improving treatment options for autoimmune disorders. An early focus for this development is systemic lupus erythematosus (SLE). The mechanism involves the activation of dNKT cells to inhibit type 1 invariant NKT (iNKT) cell activity mediated by dendritic cells.

Japanese Patent for Inflammatory Conditions

Meanwhile, Japanese patent application No. 2023-000750 titled “Prevention and Treatment of Inflammatory Conditions” covers the methodologies and compositions for effectively modulating dNKT and/or iNKT cells. This ensures robust protective measures and therapies against inflammatory, fibrotic, and autoimmune conditions through the administration of a Retinoic Acid Receptor (RAR) agonist which effectively inhibits iNKT cells in patients.

Comments from GRI Bio Leadership

Marc Hertz, PhD and CEO of GRI Bio, expressed, “The granting of these patents marks yet another milestone in our mission to expand our global patent estate. Our commitment to enhancing our IP portfolio underscores the strategic importance of our innovative NKT cell modulators and our extensive library of over 500 proprietary compounds.” This dedication reflects a powerful opportunity to effectively address unfulfilled medical needs associated with inflammatory and autoimmune diseases.

Current Development Initiatives

GRI Bio continues to develop its lead program, GRI-0621, which is currently in a Phase 2a clinical trial. This randomized, double-blind, multi-center, placebo-controlled study aims to evaluate the treatment of idiopathic pulmonary fibrosis (IPF). The initial results of the Phase 2a biomarker study are anticipated soon, with topline results expected shortly thereafter. Ongoing trials are crucial as GRI Bio endeavors to provide new solutions for patients grappling with IPF, a chronic and serious lung disease that necessitates advanced treatment approaches.

About GRI Bio, Inc.

GRI Bio, Inc. operates within the biopharmaceutical sector, focusing on revolutionary approaches to treating debilitating inflammatory, fibrotic, and autoimmune diseases. The company's therapeutic strategies revolve around targeting the activity of NKT cells, which are pivotal in regulating the inflammatory cascade. By effectively interrupting the progression of disease and aiming to restore immune balance, GRI Bio's approach presents a promising avenue for patient care. The significance of NKT cells as a vital link between innate and adaptive immune responses further emphasizes the company's commitment to innovative solutions. GRI Bio’s lead program, GRI-0621, serves as a groundbreaking oral therapeutic target against iNKT cell activity, specifically for IPF treatment. In addition to this, the company is progressing with a range of dNKT agonists aimed at systemic lupus erythematosus treatment.

Frequently Asked Questions

What are the newly granted patents from GRI Bio?

GRI Bio has obtained patents in Europe and Japan focused on NKT cell modulators aimed at treating autoimmune and inflammatory diseases.

How does GRI Bio's lead program function?

GRI-0621, GRI Bio's lead program, aims to inhibit iNKT cell activity to treat idiopathic pulmonary fibrosis and restore immune balance.

What diseases does GRI Bio target?

The company targets inflammatory, fibrotic, and autoimmune diseases through its innovative NKT cell modulators.

Who is the CEO of GRI Bio?

Marc Hertz, PhD, is the Chief Executive Officer of GRI Bio.

How can I contact GRI Bio for investor inquiries?

Investor inquiries can be directed to the JTC Team, LLC, specifically to Jenene Thomas at (908) 824-0775 or via email at GRI@jtcir.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SecondSideMedia Tackles AI Misinformation with New Platform

Updated Category News Views 0

Overcoming the AI Misinformation Maze The AI revolution isn't without its hiccups, and when machines spin their tales wrong, damage control becomes a necessity. Enter SecondSideMedia, coming out swinging with a platform specifically crafted to tackle those pesky inaccuracies AI can spit out. They launched this beauty after a successful pilot and they aren't following the...

Continue Reading
Influencer Advantage Redefines Marketing with 75,000 Partnerships

Updated Category News Views 12

Cracking the Creator Code in Modern Marketing If you're riding the rails of today's advertising scene without linking up with influencers, well, you're playing yesterday's game. Influencer Advantage is laughing in the face of old models by hitting an astronomical 75,000 creator partnerships each month. That's not just breaking records—it's obliterating them, all while...

Continue Reading
Staples Raises Over $617K for Junior Achievement

Updated Category News Views 10

Staples Strikes Gold with Fundraising Campaign Sometimes, a corporation deciding to put its weight behind a good cause is more than just a PR move. This time around, Staples has made quite an impact by raising a whopping $617,620 through its Back-to-School Round-Up Campaign to support Junior Achievement (JA) students. Customers buying pencils and paper ended up rounding...

Continue Reading
Illinois Water Flushing: Essential But Inconvenient

Updated Category News Views 2

Kicking Off Another Round of Hydrant Flushing You know what marks the transition from summer to fall in Streator just as surely as the leaves changing color? That's right, hydrant flushing season, courtesy of Illinois American Water. Beginning September 1 and stretching through October 2, Illinois American Water is diving into their yearly ritual of flushing out the water...

Continue Reading
Charbone's Q2 Growth Rooted in Distribution Gains

Updated Category News Views 3

Momentum Building for Charbone Charbone Corporation's latest quarter tells a story of transition. The company's bread isn't getting buttered on hydrogen alone anymore—it’s the industrial gases platform catching investors’ eyes. If anything, this report reveals how Charbone's spinning the wheel in a different direction. Phase 1B Approach: What's Gained Q2 wasn't just...

Continue Reading
Legal Excellence: Cooper & Trachtenberg Honored

Updated Category News Views 6

Accolades in Family Law: A Consistent Excellence Nothing says "you're doing something right" like repeated recognition from your peers, right? Miriam Cooper and Helena L. Trachtenberg of Cooper Trachtenberg Law Group seem to have nailed it again, being applauded by Best Lawyers® for their relentless dedication to family law. And when something comes up this regularly,...

Continue Reading
GCW's AI Move: Shaking Up Visibility Game

Updated Category News Views 7

A New Era for Brand Visibility It used to be simple, didn't it? Throw some cash at SEO, tweak a few keywords, and watch traffic pour in. But just like your old stock plays, visibility has a new game. GCW (Global Communication Works) is wading into these waters with SignlLabs, offering a fresh take on brand recognition in the age of artificial intelligence. It's their...

Continue Reading
Decoding Insurance Choices: Tulsa Drivers' Dilemma

Updated Category News Views 10

Insurance Jargon: Navigating the Tulsa Terrain Insurance. If you’ve ever tried to wrap your head around this beast, you know it’s not the friendliest thing on the block. For the folks in Tulsa, Oklahoma, understanding the difference between full coverage and liability insurance isn’t just an idle exercise—it's critical. There's more at stake than just a piece of...

Continue Reading
Updated Migraine Guidelines: Fresh Options for Relief

Updated Category News Views 7

New Directions in Migraine Management When it comes to that throbbing misery known as migraine, sufferers need all the help they can get. It's the kind of thing that can turn your whole day upside down—or worse, your whole month if left unchecked. The American Academy of Neurology (AAN) and the American Headache Society (AHS) have done the legwork to help. Their updated...

Continue Reading
Janet McKinnerney Bolsters Advanced IT as CFO

Updated Category News Views 7

Janet McKinnerney Takes the Helm at Advanced IT It doesn't take a Wall Street wizard to see that appointing a financial head honcho can recalibrate a company, especially in a field as critical as IT solutions and defense services. Advanced IT Concepts, the Orlando-based powerhouse, has lured in Janet McKinnerney to wear the CFO crown—and rightfully so. This gal's...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Long-term Blarcamesine Treatment Shows Promising Results

Updated Category News Views 146

Positive Outcomes from Long-term Treatment with Blarcamesine Blarcamesine, an innovative treatment for Alzheimer's disease developed by Anavex Life Sciences Corp. (NASDAQ: AVXL), has shown impressive results over an extensive clinical trial period. The recent ATTENTION-AD trial revealed that patients receiving this oral treatment for over three years demonstrated...

Continue Reading
Insights into Royce Global Trust's Fund Performance and Strategy

Updated Category News Views 140

Understanding Royce Global Trust Royce Global Trust (NYSE: RGT) is a prominent closed-end fund that strategically invests in global equities, leveraging a disciplined value approach. One of the fund's key strengths is its average weekly trading volume, which stands at approximately 104,348 shares, reflecting robust market activity. With over 50 years of experience in...

Continue Reading
Dundee Corporation Finalizes Successful Sale of TauRx Shares

Updated Category News Views 92

Dundee Corporation Concludes Sale of TauRx Shares Dundee Corporation (TSX: DC) recently announced a successful transaction involving the sale of 8,000 shares of TauRx Pharmaceuticals Ltd. for a total of US$1 million. This significant move follows the completion of the necessary board approval that the company secured from TauRx. The shares were sold to a private investor...

Continue Reading
Three Promising Stocks for Uncertain Economic Times

Updated Category News Views 155

Understanding the Current Economic Climate Investors are feeling increasingly cautious about the economic future, mainly due to signs pointing to a possible recession. Economic indicators have shown fluctuations, drawing attention from financial analysts and retail traders alike. Many are seeking opportunities that will help mitigate risks in turbulent times. 1. Waste...

Continue Reading
Churchill Downs Incorporates Major Share Repurchase Initiative

Updated Category News Views 97

Churchill Downs Incorporated Unveils $500 Million Buyback Plan Churchill Downs Incorporated (Nasdaq: CHDN) has taken a significant step in its strategic financial planning by announcing a $500 million share repurchase program. The decision comes after the company's Board of Directors approved the initiative to effectively replace a similar size program from earlier this...

Continue Reading